Skip to content

State coverage

Oklahoma

State Medicaid · 2 documents cited

Medicaid, for obesity: Does not cover. The conditions and the appeal deadline are in the summary below.

At a glance

Does not cover
Medicaid, for obesity
Calls the category adiposity-based chronic disease, then closes the obesity-alone door three times over.
Appeal deadline
Not published here. Oklahoma's official rules sit on a host that refuses every request, and the agency says its own online copies are unofficial — so the filing window could not be read from the document that binds you. Go by the date on your notice. Federal ceiling: no more than 90 days.
Primary source
Oklahoma Health Care Authority, Prior Authorization Criteria 2026 — Metabolic Disorders
Date read
September 2026

Denise Ramirez, Coverage Editor · Who writes this site

Oklahoma does not have a weight-loss drug category. It has one called Adiposity-Based Chronic Disease, and that is not a euphemism — it changes how the criteria are written.

Framing obesity as a chronic disease would normally point toward broader coverage. Here it does the opposite. Each drug gets its own indication and each one carries the same sentence, in slightly different words, saying it will not be approved for an obese member who does not also have the other condition. Wegovy needs established cardiovascular disease or liver disease. Zepbound needs sleep apnea. The state writes that door shut three separate times.

There is one real weight-management route, and it is narrow. Imcivree is covered for chronic weight management from age two, but only for obesity caused by named genetic conditions, confirmed by genetic testing submitted with the request.

Oklahoma also publishes less than it looks like it does. Its rules are on a site that will not answer, and the copies on its own website say on every page that they are unofficial — so there is no appeal deadline on this page.

What we could verify for Oklahoma

Oklahoma files these drugs under a disease name rather than a weight-loss one. Its 2026 criteria page for the class is headed "Metabolic Disorders" and the section itself "Adiposity-Based Chronic Disease (ABCD) Medications", covering Imcivree, Wegovy and Zepbound. The page is stamped "Last Modified on Aug 17, 2026".

Oklahoma Health Care Authority, Prior Authorization Criteria 2026 — Metabolic Disorders, effective August 2026 · source

Zepbound is a sleep apnea drug here, and the criteria say so twice over: "An FDA approved indication of moderate to severe OSA in members with obesity; and Zepbound® will not be approved for obese members in the absence of OSA" — the source runs straight on into the next condition It also requires an AHI of at least 15 on a sleep study, a BMI of at least 30, no central or mixed sleep apnea, and that the "Member does not have type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM)" with "a hemoglobin A1C (HbA1c) <6.5%".

Oklahoma Health Care Authority, Prior Authorization Criteria 2026 — Metabolic Disorders, effective August 2026 · source

Wegovy has two doors and both shut on obesity alone. For heart risk the criteria require established cardiovascular disease and state that Wegovy "will not be approved for obese or overweight members in the absence of established CVD", with the member "45 years of age or older". For liver disease they state it "will not be approved for obese members in the absence of MASH", with fibrosis confirmed by FibroScan, an Enhanced Liver Fibrosis score or a biopsy.

Oklahoma Health Care Authority, Prior Authorization Criteria 2026 — Metabolic Disorders, effective August 2026 · source

One genuine weight-management route survives and it is genetic. Imcivree is approved for "chronic weight management in adult and pediatric members 2 years of age and older with obesity due to" POMC, PCSK1 or leptin receptor deficiency, or Bardet-Biedl syndrome — each confirmed by "molecular genetic testing" whose results "must be submitted" with the request.

Oklahoma Health Care Authority, Prior Authorization Criteria 2026 — Metabolic Disorders, effective August 2026 · source

Oklahoma tells you itself that the rules on its website are not the rules. Every OHCA policy page carries the line: "The OHCA rules found on this Web site are unofficial. The official rules are published by the Oklahoma Secretary of State Office of Administrative Rules as Title 317 of the Oklahoma Administrative Code." That official site, rules.ok.gov, answered 403 to every attempt in this session, including with a full browser fingerprint, while other state sites answered normally — so the binding text of the appeal rule could not be read from its publisher.

Oklahoma Health Care Authority, Policies and Rules — Administrative Appeals · source

Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.

If the appeal fails, or you cannot wait

Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.

  • CoreAge RxAdvertises $99 a month for compounded semaglutide, flat across doses. Read the terms before you sign up: the lander our link opens has shown $149 rather than $99, and a consultation fee can be charged on top and may not be refundable.
  • OakFlat price across doses, free shipping with supplies.
  • Care Bare RxNames its pharmacies with addresses; sells brand Ozempic as well as compounded.
  • Gala HealthAll doses one price, but the advertised rate needs a yearly subscription.
  • Synergy RxProviders licensed in your state; publishes no GLP-1 price before the consult.
  • Breeze MedsServes all 50 states; publishes a starting price only.

Prices in those notes were read from each company's own site in August 2026 and change often. Check the current number before you buy.

Where this comes from

  1. Oklahoma Health Care Authority, Prior Authorization Criteria 2026 — Metabolic Disorders, effective August 2026 — oklahoma.gov/ohca/providers/types/pharmacy/prior-authorization/2026/meta
  2. Oklahoma Health Care Authority, Policies and Rules — Administrative Appeals — oklahoma.gov/ohca/policies-and-rules/xpolicy/grievance-procedures-and-pr

Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.